SCHEMBL810941

SCHEMBL810941

CC(CCCCCCCCCCCCCCC(=O)O)=C(C)C(=O)O

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 5/20 0.57
LMNA P02545 2/20 0.57
NFKB1 P19838 1/20 0.57
PMP22 Q01453 1/20 0.57
GPR84 Q9NQS5 8/20 0.52
PPARG P37231 7/20 0.52
PPARD Q03181 7/20 0.52
PPARA Q07869 7/20 0.52
HDAC11 Q96DB2 5/20 0.52
PTPN1 P18031 3/20 0.52
ALDH1A1 P00352 2/20 0.52
TLR2 O60603 2/20 0.52
TDP1 Q9NUW8 2/20 0.52
FABP4 P15090 2/20 0.52
FFAR1 O14842 2/20 0.52
FFAR4 Q5NUL3 2/20 0.52
SLC22A6 Q4U2R8 1/20 0.52
SLC22A8 Q8TCC7 1/20 0.52
MEN1 O00255 1/20 0.52
ESR1 P03372 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL811739 1.00 TSHR (0.57) TSHRLMNANFKB1PMP22GPR84
SCHEMBL810940 1.00 TSHR (0.57) TSHRLMNANFKB1PMP22GPR84
SCHEMBL811493 1.00 TSHR (0.57) TSHRLMNANFKB1PMP22GPR84
SCHEMBL28726986 1.00 TSHR (0.57) TSHRLMNANFKB1PMP22GPR84
SCHEMBL15363963 0.98 LMNA (0.55) TSHRLMNANFKB1PMP22GPR84
SCHEMBL15363966 0.98 LMNA (0.55) TSHRLMNANFKB1PMP22GPR84
SCHEMBL15363970 0.93 SLC22A6 (0.55) TSHRLMNANFKB1PMP22GPR84
SCHEMBL15363968 0.93 SLC22A6 (0.55) TSHRLMNANFKB1PMP22GPR84
SCHEMBL3026650 0.84 FNTA (0.67) TSHRGPR84PPARGPPARDPPARA
SCHEMBL811607 0.84 FNTA (0.67) TSHRGPR84PPARGPPARDPPARA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2389349-A2 METHODS FOR PRODUCING DODECANEDIOIC ACID AND DERIVATIVES THEREOF Draths Corporation (US) 2011-11-30 EP disclosed
US-8041434-B2 Implantable medical electrical lead bodies providing improved electrode contact MEDTRONIC, INC. (US) 2011-10-18 US disclosed
US-7906663-B2 Process for co-producing olefins and diesters or diacids starting from unsaturated fats IFP Energies Nouvelles (FR) 2011-03-15 US disclosed
EP-1810961-B1 Method of co-producing olefins and diesters or diacids by homometathesis of unsaturated fatty bodies in non-aqueous ionic liquids INST FRANCAIS DU PETROLE (FR) 2010-12-29 EP disclosed
WO-2010085712-A2 METHODS FOR PRODUCING DODECANEDIOIC ACID AND DERIVATIVES THEREOF DRATHS CORPORATION (US) 2010-07-29 WO disclosed
US-7754904-B2 Process for co-producing olefins and diesters or diacids by homomethathesis of unsaturated fats in non-aqueous ionic liquids INSTITUT FRANCAIS DU PETROLE (FR) 2010-07-13 US disclosed
EP-1810960-B1 Method of co-producing olefins and diesters or diacids from unsaturated fatty bodies INST FRANCAIS DU PETROLE (FR) 2009-11-18 EP disclosed
US-20070179307-A1 PROCESS FOR CO-PRODUCING OLEFINS AND DIESTERS OR DIACIDS STARTING FROM UNSATURATED FATS INSTITUT FRANCAIS DU PETROLE (FR) 2007-08-02 US disclosed
US-20070179302-A1 PROCESS FOR CO-PRODUCING OLEFINS AND DIESTERS OR DIACIDS BY HOMOMETHATHESIS OF UNSATURATED FATS IN NON-AQUEOUS IONIC LIQUIDS INSTITUT FRANCAIS DU PETROLE (FR) 2007-08-02 US disclosed
EP-1810961-A1 Method of co-producing olefins and diesters or diacids by homometathesis of unsaturated fatty bodies in non-aqueous ionic liquids Institut Français du Pétrole (FR) 2007-07-25 EP disclosed
EP-1810960-A1 Method of co-producing olefins and diesters or diacids from unsaturated fatty bodies Institut Français du Pétrole (FR) 2007-07-25 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070179302-A1 PROCESS FOR CO-PRODUCING OLEFINS AND DIESTERS OR DIACIDS BY HOMOMETHATHESIS OF UNSATURATED FATS IN NON-AQUEOUS IONIC LIQUIDS FADS2, SCD, FADS1 TSHR 4466/4885LMNA 4227/4885NFKB1 2223/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.